Pulmozyme (Genentech): Global Drug Outlook Report 2019 with Sales for Cystic Fibrosis Through 2016-2025
Dublin, June 28, 2019 (GLOBE NEWSWIRE) -- The "Pulmozyme" report has been added to ResearchAndMarkets.com's offering.
Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by genetically engineered Chinese hamster ovary cells.
In patients with cystic fibrosis, high concentrations of extracellular DNA are commonly found in the sputum as a result of the body's innate response to respiratory infections.
This increases the viscoelasticity of the mucus, reducing pulmonary function and increasing risk of further infection. Pulmozyme hydrolyzes DNA, reducing the viscoelasticity of sputum and encouraging its clearance.
Key Topics Covered
- Drug Overview
- Product Profiles
- Pulmozyme: Cystic fibrosis
List of Figures
Figure 1: Pulmozyme for cystic fibrosis - SWOT analysis
Figure 2: The authors drug assessment summary of Pulmozyme for cystic fibrosis
Figure 3: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country, 2016-25
List of Tables
Table 1: Pulmozyme drug profile
Table 2: Pulmozyme pivotal trial data in cystic fibrosis
Table 3: Pulmozyme sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016-25
For more information about this report visit https://www.researchandmarkets.com/r/1pn1lk
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
